Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Development and clinical translation of ex vivo gene therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1126/science.aan4672
10.1126/science.aan4672 · External reference
10.1056/nejmra1706910
10.1056/nejmra1706910 · External reference
Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid
10.1038/171737a0 · 1953 · External reference
Role of recombinant DNA technology to improve life
2016 · External reference
Construction of biologically functional bacterial plasmids in vitro
10.1073/pnas.70.11.3240 · 1973 · External reference
Molecular biology, nucleic acids, and the future of medicine
10.1353/pbm.1966.0027 · 1966 · External reference
10.1038/ng1092-93
10.1038/ng1092-93 · External reference
10.1126/science.175.4025.949
10.1126/science.175.4025.949 · External reference
10.1089/hum.1991.2.2-107
10.1089/hum.1991.2.2-107 · External reference
10.1038/420116a
10.1038/420116a · External reference
10.1016/j.jconrel.2012.04.008
10.1016/j.jconrel.2012.04.008 · External reference
10.1089/hum.2014.2542
10.1089/hum.2014.2542 · External reference
Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease
1996 · External reference
10.5772/18155
10.5772/18155 · External reference
10.1038/sj.mt.6300350
10.1038/sj.mt.6300350 · External reference
Development of the First World Health Organization lentiviral vector standard: toward the production control and standardization of lentivirus-based gene therapy products
10.1089/hgtb.2017.078 · 2017 · External reference
10.1007/s40259-017-0234-5
10.1007/s40259-017-0234-5 · External reference
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
10.2174/1566523213666131125095046 · 2013 · External reference
Retroviral vectors: new applications for an old tool
10.1038/sj.gt.3302363 · 2004 · External reference
High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range
10.1073/pnas.81.20.6349 · 1984 · External reference
Retroviral gene therapy in Germany with a view on previous experience and future perspectives
10.1038/s41434-021-00237-x · 2021 · External reference
10.1126/science.288.5466.669
10.1126/science.288.5466.669 · External reference
10.1038/s41576-020-00298-5
10.1038/s41576-020-00298-5 · External reference
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
10.1038/s41409-022-01691-w · 2022 · External reference
Gene therapies for primary immune deficiencies
2021 · External reference
10.1016/j.drudis.2021.03.021
10.1016/j.drudis.2021.03.021 · External reference
10.1016/j.gendis.2019.07.004
10.1016/j.gendis.2019.07.004 · External reference
The genetic basis of severe combined immunodeficiency and its variants
2012 · External reference
10.1016/j.jaci.2020.05.055
10.1016/j.jaci.2020.05.055 · External reference
10.1007/s10875-017-0433-3
10.1007/s10875-017-0433-3 · External reference
10.1126/science.3520819
10.1126/science.3520819 · External reference
10.1089/hum.2017.175
10.1089/hum.2017.175 · External reference
10.1126/science.270.5235.475
10.1126/science.270.5235.475 · External reference
10.1126/science.270.5235.470
10.1126/science.270.5235.470 · External reference
10.1182/blood-2002-09-2800
10.1182/blood-2002-09-2800 · External reference
10.1056/nejmoa012616
10.1056/nejmoa012616 · External reference
10.1016/s0140-6736(04)17590-9
10.1016/s0140-6736(04)17590-9 · External reference
The transformative potential of HSC gene therapy as a genetic medicine
2021 · External reference
10.1089/hum.2015.137
10.1089/hum.2015.137 · External reference
10.1016/s1081-1206(10)60504-2
10.1016/s1081-1206(10)60504-2 · External reference
10.1056/nejmoa1000164
10.1056/nejmoa1000164 · External reference
10.1126/science.1088547
10.1126/science.1088547 · External reference
10.1172/jci35798
10.1172/jci35798 · External reference
10.1172/jci35700
10.1172/jci35700 · External reference
10.1056/nejmoa1404588
10.1056/nejmoa1404588 · External reference
10.1038/sj.mt.6300393
10.1038/sj.mt.6300393 · External reference
T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency
10.1186/s13073-018-0580-z · 2018 · External reference
Immune reconstitution after gene therapy approaches in patients with X-linked severe combined immunodeficiency disease
10.3389/fimmu.2020.608653 · 2020 · External reference
Preclinical development of autologous hematopoietic stem cell-based gene therapy for immune deficiencies: a journey from mouse cage to bed side
10.3390/pharmaceutics12060549 · 2020 · External reference
Gene therapy for severe combined immunodeficiencies and beyond
10.1084/jem.20190607 · 2020 · External reference
A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders
10.1038/s41467-022-28762-2 · 2022 · External reference
10.1038/s41591-021-01650-w
10.1038/s41591-021-01650-w · External reference
Progress and perspectives in the development of lentiviral vector producer cells
10.1002/biot.202000017 · 2021 · External reference
Development of lentiviral vectors for gene therapy for human diseases
10.1182/blood.v95.8.2499.008k35_2499_2504 · 2000 · External reference
10.1038/s41375-018-0106-0
10.1038/s41375-018-0106-0 · External reference
10.1038/s41392-021-00487-6
10.1038/s41392-021-00487-6 · External reference
10.1056/nejmoa1815408
10.1056/nejmoa1815408 · External reference
Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency
10.1126/scitranslmed.aad8856 · 2016 · External reference
10.1089/hgtb.2012.150
10.1089/hgtb.2012.150 · External reference
10.1182/blood-2009-10-250209
10.1182/blood-2009-10-250209 · External reference
10.1126/science.1070104
10.1126/science.1070104 · External reference
10.1056/nejmoa0805817
10.1056/nejmoa0805817 · External reference
10.1089/humc.2016.191
10.1089/humc.2016.191 · External reference
10.15252/emmm.201707573
10.15252/emmm.201707573 · External reference
10.1182/blood-2016-01-688226
10.1182/blood-2016-01-688226 · External reference
10.1056/nejmoa2027675
10.1056/nejmoa2027675 · External reference
10.1016/j.jaci.2009.07.053
10.1016/j.jaci.2009.07.053 · External reference
10.1016/j.iac.2010.02.002
10.1016/j.iac.2010.02.002 · External reference
Importance of neonatal screening for primary immunodeficiencies
10.3345/cep.2021.00283 · 2021 · External reference
In utero gene therapy for primary immunodeficiencies
10.1097/grf.0000000000000652 · 2021 · External reference
10.1097/mop.0000000000001075
10.1097/mop.0000000000001075 · External reference
10.1007/s12185-016-2030-2
10.1007/s12185-016-2030-2 · External reference
Lentiviral hematopoietic stem cell gene therapy in patients with wiskott-Aldrich syndrome
10.1542/peds.2014-1817hhhh · 2014 · External reference
10.1126/science.1233151
10.1126/science.1233151 · External reference
10.1056/nejmoa1003548
10.1056/nejmoa1003548 · External reference
Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome
2006 · External reference
A Case of two adult brothers with wiskott-aldrich syndrome, one treated with gene therapy and one with HLA-identical hematopoietic stem cell transplantation
2021 · External reference
Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy
10.1021/mp200132u · 2011 · External reference
Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome
10.1001/jama.2015.3253 · 2015 · External reference
Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients
10.1038/sj.gt.3302863 · 2007 · External reference
Hematopoietic tumors in a mouse model of X-linked chronic granulomatous disease after lentiviral vector-mediated gene therapy
10.1016/j.ymthe.2020.09.030 · 2021 · External reference
Chronic granulomatous disease of the upper airway
2021 · External reference
10.1182/bloodadvances.2020003224
10.1182/bloodadvances.2020003224 · External reference
Gene therapy for chronic granulomatous disease: current status and future perspectives
10.2174/1566523214666140918113201 · 2014 · External reference
10.1038/nm1393
10.1038/nm1393 · External reference
10.1038/mt.2010.232
10.1038/mt.2010.232 · External reference
Gene therapy for chronic granulomatous disease
2006 · External reference
10.1038/nm.2088
10.1038/nm.2088 · External reference
Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions
10.1016/j.jaci.2015.11.028 · 2016 · External reference
Recent advances in gene therapy and modeling of chronic granulomatous disease
2019 · External reference
10.1038/s41591-019-0735-5
10.1038/s41591-019-0735-5 · External reference
10.1016/j.jaci.2020.05.024
10.1016/j.jaci.2020.05.024 · External reference
10.21203/rs.3.rs-596185/v1
10.21203/rs.3.rs-596185/v1 · External reference
10.1126/science.aba3827
10.1126/science.aba3827 · External reference
10.1002/14651858.cd008708.pub5
10.1002/14651858.cd008708.pub5 · External reference
A small key for a heavy door: genetic therapies for the treatment of hemoglobinopathies
10.3389/fgeed.2020.617780 · 2021 · External reference
10.1089/hum.2016.037
10.1089/hum.2016.037 · External reference
10.1089/hum.2017.228
10.1089/hum.2017.228 · External reference
Sickle cell anemia, a molecular disease
1949 · External reference
Sickle cell disease
10.1016/s0140-6736(17)30193-9 · 2017 · External reference
Gene therapy: targeting beta-thalassaemia
10.1038/467277a · 2010 · External reference
10.1056/nejmoa1705342
10.1056/nejmoa1705342 · External reference
10.1056/nejmoa2031054
10.1056/nejmoa2031054 · External reference
The present and future global burden of the inherited disorders of hemoglobin
10.1016/j.hoc.2015.11.004 · 2016 · External reference
Locus control region mediated regulation of adult beta-globin gene expression
10.1002/jcb.21820 · 2008 · External reference
10.1182/blood-2002-04-1104
10.1182/blood-2002-04-1104 · External reference
10.1126/science.1065806
10.1126/science.1065806 · External reference
10.1038/35017565
10.1038/35017565 · External reference
The human beta globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice
10.1182/blood.v90.11.4602 · 1997 · External reference
10.1182/blood.v90.9.3332
10.1182/blood.v90.9.3332 · External reference
A dominant control region from the human beta-globin locus conferring integration site-independent gene expression
10.1038/338352a0 · 1989 · External reference
10.1038/331035a0
10.1038/331035a0 · External reference
Towards more successful gene therapy clinical trials for beta-thalassemia
10.2174/15665240113139990064 · 2013 · External reference
Engineering globin gene expression
2019 · External reference
10.1016/j.hoc.2017.06.010
10.1016/j.hoc.2017.06.010 · External reference
10.1177/2040620716653729
10.1177/2040620716653729 · External reference
Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein
10.1073/pnas.84.8.2411 · 1987 · External reference
10.1016/0092-8674(87)90584-8
10.1016/0092-8674(87)90584-8 · External reference
10.1038/nature09328
10.1038/nature09328 · External reference
10.1089/hum.2016.007
10.1089/hum.2016.007 · External reference
Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease
10.2174/1566523214666141127095336 · 2015 · External reference
Evolving treatment paradigms in sickle cell disease
10.1182/asheducation-2017.1.440 · 2017 · External reference
10.1056/nejmoa1609677
10.1056/nejmoa1609677 · External reference
10.1182/blood-2019-127393
10.1182/blood-2019-127393 · External reference
Exploring the drivers of potential clinical benefit in initial patients treated in the Hgb-206 study of lentiglobin for Sickle Cell Disease (SCD) gene therapy
10.1182/blood-2019-128814 · 2019 · External reference
10.1056/nejmoa2117175
10.1056/nejmoa2117175 · External reference
10.1056/nejmoa2109167
10.1056/nejmoa2109167 · External reference
Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders
10.1038/s41467-019-12456-3 · 2019 · External reference
10.1016/j.ymthe.2019.09.020
10.1016/j.ymthe.2019.09.020 · External reference
Peroxisome biogenesis disorders
2020 · External reference
Human disorders of peroxisome metabolism and biogenesis
10.1016/j.bbamcr.2015.11.015 · 2016 · External reference
10.1177/0192623307309925
10.1177/0192623307309925 · External reference
10.1089/hum.2017.160
10.1089/hum.2017.160 · External reference
10.1172/jci30230
10.1172/jci30230 · External reference
Mesenchymal stem cell-based therapy for lysosomal storage diseases and other neurodegenerative disorders
2022 · External reference
Hematopoietic stem cell transplantation with mesenchymal stromal cells in children with metachromatic leukodystrophy
10.1089/scd.2021.0352 · 2022 · External reference
10.1111/dmcn.14885
10.1111/dmcn.14885 · External reference
CNS-targeting therapies for lysosomal storage diseases
10.3389/fmolb.2020.559804 · 2020 · External reference
Partial enzyme deficiencies: residual activities and the development of neurological disorders
1983 · External reference
10.1038/s41572-018-0025-4
10.1038/s41572-018-0025-4 · External reference
10.1038/s41573-019-0036-1
10.1038/s41573-019-0036-1 · External reference
Therapeutic approaches in lysosomal storage diseases
10.3390/biom11121775 · 2021 · External reference
Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1/2 clinical trial
10.1016/j.ymgme.2020.07.002 · 2020 · External reference
Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy
10.1186/s40348-020-00103-7 · 2020 · External reference
Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies
10.1182/bloodadvances.2017010645 · 2018 · External reference
Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy
10.1016/j.bbmt.2013.01.010 · 2013 · External reference
Haematopoietic stem cell transplantation does not retard disease progression in the psycho-cognitive variant of late-onset metachromatic leukodystrophy
10.1007/s10545-010-9240-1 · 2010 · External reference
Gene therapy offers new hope for children with metachromatic leukodystrophy
10.1016/s0140-6736(22)00057-5 · 2022 · External reference
Approach to patients with neurometabolic diseases who show characteristic signs and symptoms
2020 · External reference
Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan
10.1016/j.ymgme.2021.05.004 · 2021 · External reference
10.1089/hum.2019.190
10.1089/hum.2019.190 · External reference
Inherited metabolic rare disease
2010 · External reference
10.1016/j.bbamcr.2008.12.001
10.1016/j.bbamcr.2008.12.001 · External reference
Neuroinflammatory paradigms in lysosomal storage diseases
2015 · External reference
Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders
2015 · External reference
10.3389/fneur.2021.737398
10.3389/fneur.2021.737398 · External reference
10.15252/emmm.201708213
10.15252/emmm.201708213 · External reference
10.1038/nature24487
10.1038/nature24487 · External reference
10.1038/nm1504
10.1038/nm1504 · External reference
10.1007/s13555-021-00561-5
10.1007/s13555-021-00561-5 · External reference
10.3389/fgene.2021.658295
10.3389/fgene.2021.658295 · External reference
10.1111/exd.14314
10.1111/exd.14314 · External reference
Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa
10.1080/14712598.2020.1740678 · 2020 · External reference
10.1111/bjd.18921
10.1111/bjd.18921 · External reference
Hereditary bullous diseases: current and innovative models to study the skin blistering disease epidermolysis bullosa
2020 · External reference
10.1038/s41572-020-0210-0
10.1038/s41572-020-0210-0 · External reference
Transgenic epidermal cultures for junctional epidermolysis bullosa - 5-year outcomes
10.1056/nejmoa2108544 · 2021 · External reference
Toward treatment and cure of epidermolysis bullosa
2019 · External reference
Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa
10.1001/jama.2016.15588 · 2016 · External reference
EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa
10.1111/bjd.18559 · 2020 · External reference
10.1056/nejmra1706169
10.1056/nejmra1706169 · External reference
10.1126/science.aar6711
10.1126/science.aar6711 · External reference
10.1016/j.cell.2017.12.002
10.1016/j.cell.2017.12.002 · External reference
10.1016/j.cell.2020.03.001
10.1016/j.cell.2020.03.001 · External reference
10.1038/s41577-020-0306-5
10.1038/s41577-020-0306-5 · External reference
Recent advances in CAR-T cell engineering
10.1186/s13045-020-00910-5 · 2020 · External reference
10.1038/s41408-021-00459-7
10.1038/s41408-021-00459-7 · External reference
10.1016/0092-8674(91)90314-o
10.1016/0092-8674(91)90314-o · External reference
Gene therapy for cancer treatment: past, present and future
10.3121/cmr.4.3.218 · 2006 · External reference
10.1056/nejmoa1707447
10.1056/nejmoa1707447 · External reference
10.1016/j.ymthe.2016.10.020
10.1016/j.ymthe.2016.10.020 · External reference
10.1182/blood-2016-02-629063
10.1182/blood-2016-02-629063 · External reference
10.1016/j.drudis.2018.02.012
10.1016/j.drudis.2018.02.012 · External reference
From the guest editor: the rise of CAR therapy: the CD19 paradigm, and beyond
2014 · External reference
10.1182/blood-2010-04-281931
10.1182/blood-2010-04-281931 · External reference
10.1056/nejmoa1103849
10.1056/nejmoa1103849 · External reference
Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs Physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma
10.1007/s40261-021-01100-y · 2022 · External reference
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
10.1182/bloodadvances.2021006922 · 2022 · External reference
Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia
2022 · External reference
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
10.1038/s41408-022-00629-1 · 2022 · External reference
Brexucabtagene autoleucel: a novel chimeric antigen receptor T-cell therapy for the treatment of mantle cell lymphoma
10.1177/10600280211026338 · 2022 · External reference
Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis
10.1002/ajh.26233 · 2021 · External reference
10.1016/s0140-6736(21)00933-8
10.1016/s0140-6736(21)00933-8 · External reference
The advent of CAR T-cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice
2020 · External reference
CAR T-cell therapy: full speed ahead
10.1002/hon.2591 · 2019 · External reference
CAR T cell therapy: a new era for cancer treatment (Review)
2019 · External reference
Nomenclature for endogenous retrovirus (ERV) loci
10.1186/s12977-018-0442-1 · 2018 · External reference
Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer
10.1006/mthe.2000.0123 · 2000 · External reference
10.1053/paor.1999.0003
10.1053/paor.1999.0003 · External reference
10.1128/jvi.72.3.1769-1774.1998
10.1128/jvi.72.3.1769-1774.1998 · External reference
10.1016/0042-6822(91)90990-s
10.1016/0042-6822(91)90990-s · External reference
10.1128/jvi.62.10.3802-3806.1988
10.1128/jvi.62.10.3802-3806.1988 · External reference
10.1128/jvi.61.5.1639-1646.1987
10.1128/jvi.61.5.1639-1646.1987 · External reference
10.1016/0092-8674(83)90344-6
10.1016/0092-8674(83)90344-6 · External reference
10.1089/hgtb.2017.098
10.1089/hgtb.2017.098 · External reference
Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives
10.1186/s12967-016-1047-x · 2016 · External reference
10.1038/nature14226
10.1038/nature14226 · External reference
Current advances in retroviral gene therapy
10.2174/156652311795684740 · 2011 · External reference
RNA sequences in the Moloney murine leukemia virus genome bound by the Gag precursor protein in the yeast three-hybrid system
10.1128/jvi.78.14.7677-7684.2004 · 2004 · External reference
Generation of retroviral packaging and producer cell lines for large-scale vector production with improved safety and titer
2003 · External reference
10.1126/science.1068893
10.1126/science.1068893 · External reference
Laboratory-scale lentiviral vector production and purification for enhanced ex vivo and in vivo genetic engineering
2020 · External reference
Production of lentiviral vectors using suspension cells grown in serum-free media
2020 · External reference
Designing lentiviral vectors for gene therapy of genetic diseases
10.3390/v13081526 · 2021 · External reference
Gene editing advances on all fronts
10.1038/s41591-021-01607-z · 2021 · External reference
10.1056/nejmra1913421
10.1056/nejmra1913421 · External reference
10.1016/j.cell.2014.05.010
10.1016/j.cell.2014.05.010 · External reference
Transcription activator-like effector nucleases enable efficient plant genome engineering
10.1104/pp.112.205179 · 2013 · External reference
10.1016/j.cell.2013.04.025
10.1016/j.cell.2013.04.025 · External reference
10.1038/nprot.2013.143
10.1038/nprot.2013.143 · External reference
10.1126/science.1231143
10.1126/science.1231143 · External reference
Compact designer TALENs for efficient genome engineering
2013 · External reference
10.1038/nprot.2011.431
10.1038/nprot.2011.431 · External reference
10.1038/s41587-020-0561-9
10.1038/s41587-020-0561-9 · External reference
CRISPR/Cas9 in genome editing and beyond
2016 · External reference
10.1016/j.biotechadv.2014.12.006
10.1016/j.biotechadv.2014.12.006 · External reference
10.1056/nejmoa0802905
10.1056/nejmoa0802905 · External reference
Ten years HIV free: an interview with “The Berlin Patient,” Timothy Ray Brown
10.20411/pai.v2i3.226 · 2017 · External reference
I am the Berlin patient: a personal reflection
10.1089/aid.2014.0224 · 2015 · External reference
The London patient
10.1089/aid.2020.0058 · 2020 · External reference
10.1016/s2352-3018(20)30069-2
10.1016/s2352-3018(20)30069-2 · External reference
10.1038/s41591-020-0840-5
10.1038/s41591-020-0840-5 · External reference
Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin
2022 · External reference
Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia
2011 · External reference
10.1182/blood-2011-03-325258
10.1182/blood-2011-03-325258 · External reference
10.3389/fgene.2019.00868
10.3389/fgene.2019.00868 · External reference
10.1371/journal.pone.0004211
10.1371/journal.pone.0004211 · External reference
Prime editing: genome editing for rare genetic diseases without double-strand breaks or donor DNA
2020 · External reference
10.1038/s41586-019-1711-4
10.1038/s41586-019-1711-4 · External reference
Targeted RNA editing: novel tools to study post-transcriptional regulation
2021 · External reference
10.1038/s41592-019-0323-0
10.1038/s41592-019-0323-0 · External reference
10.1126/science.aax7063
10.1126/science.aax7063 · External reference
CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
2021 · External reference
10.1016/j.stem.2017.10.010
10.1016/j.stem.2017.10.010 · External reference
